The leading cause of gynecological cancer-related morbidity and mortality is ovarian cancer
(OC), which is dubbed a silent killer. Currently, OC is a target of intense biomarker research …

In patients with advanced ovarian carcinomas, the first-line treatment has historically relied
on debulking surgery and platinum-based chemotherapy. If the major therapeutic/prognostic …

Simple Summary Epithelial ovarian cancer is one of the most lethal cancers in women and is
typically diagnosed at an advanced-stage. Historically, primary tumor reductive surgery was …

Background CA-125 is a clinical biomarker with predictive effect on the prognosis of different
cancers. Numerous clinical trials have been conducted to investigate the possibility of using …

Objective: Neoadjuvant chemotherapy (NACT) is one kind of treatment for advanced stage
ovarian cancer patients. However, due to the nature of tumor heterogeneity, the patients' …

Objective Serum human epididymis protein 4 (HE4) and transthyretin (TTR) are new
markers for ovarian cancer. We compared HE4 and TTR with the gold marker CA-125 for the …

Objectives We examined the blood concentrations of Carbohydrate Antigen 125-Thomsen-
nouveau (CA125-Tn) and anti-Müllerian hormone (AMH) in epithelial ovarian cancer (EOC) …

Clinical utility of new biomarkers often requires the identification of their optimal threshold.
This external validation study was conducted to assess the performance of the preoperative …

Abstract Background Optimal cytoreduction (macroscopic Residual Tumor, RT= 0) is the
best survival predictor factor in epithelial ovarian cancer (EOC). It doesn't exist a …

Application values of CA125 combined with CA199 and ultrasound combined with
computed tomography (CT) in the clinical diagnosis of ovarian cancer were compared. A …